How Do You Stop Suicidal Thoughts? Ketamine Can Clear Them in Hours
By Michael Alvear, Health Author & Independent Researcher
My research is published on these scholarly platforms:
Last Updated:
What To Do If There’s An Immediate Suicide Crisis
If you might hurt yourself today, use one of these now:
If you have already hurt yourself, took pills, have a weapon, or cannot stop yourself, call 911 or go to the ER now.
A Suicide Crisis Needs Ketamine, Not Just Containment
Most People Don’t Know Ketamine Can Clear Suicidal Thoughts in Hours
If you are reading this because suicidal thoughts won’t stop — or because someone you love is trapped in that pain right now — here is what the medical establishment has not told you: intravenous ketamine can eradicate suicidal ideation within hours. Not reduce it. Not manage it. Eradicate it. In a randomized, double-blind emergency department trial, a single IV infusion eliminated suicidal ideation in 88% of acutely suicidal patients within three hours, compared with 33% receiving placebo. In a multicenter hospital trial of voluntarily hospitalized patients with severe suicidal ideation, 63% receiving IV ketamine reached full remission by Day 3, compared with 31.6% receiving standard care plus placebo. The data is not preliminary. The treatment is not experimental. People are dying because they do not know it exists.
49,316 Americans Died by Suicide Last Year. 83% Had Seen a Doctor First.
In 2023, 49,316 Americans died by suicide — one death every 11 minutes. A NIMH-funded longitudinal study of nearly 6,000 suicide decedents found that 83% had received health care in the year before their death. 45% had seen their primary care physician within the month before they died. These were not people who fell through the cracks of an inaccessible system. They were inside the system. They were seen, assessed, and sent back into their lives with the same tools that were already failing them — antidepressants that require four to six weeks to produce measurable change, and hospitalization that keeps a body physically safe for five days without touching the neurological state generating the desire to die. A proven biological intervention that can eradicate suicidal ideation within hours existed the entire time. Most of those 49,316 people were never told about it.
If You Are the Person in Pain Right Now
What you are experiencing is not a character defect or a permanent condition. It is a medical state — one that a proven biological intervention can interrupt within hours. Read this page. Then make the call.
If You Are a Family Member or Friend Searching for Something More Than a Hotline
The system will tell you to wait. You do not have to accept that. A treatment exists that the ER is almost certainly not offering your loved one. This page tells you exactly what it is, what the evidence proves, and how to demand it.
What the ER Can Do: Keep Someone Alive. What It Cannot Do: Stop the Pain.
Entering an emergency room while suicidal means entering a risk-management system, not a pain-relief system. You will be asked to change into a gown. Your belongings will be removed. You will be placed under observation. If you arrive agitated, staff will administer sedatives or antipsychotics — not to treat suicidal thinking, but to make you manageable enough to assess. If you are calm but still actively suicidal, you will likely enter psychiatric boarding: hours or days in a monitored room, waiting for an inpatient psychiatric bed to open, while the cognitive agony that brought you there continues completely untreated.
Psychiatric Boarding: What the Data Shows About Wait Times
This is not speculation about how ERs operate. A 2020 study published in the Journal of the American College of Emergency Physicians found that psychiatric boarding times in U.S. emergency departments averaged 6.8 hours, with patients in some facilities waiting more than 24 hours for psychiatric placement. During that wait, the standard pharmacological options offered to suicidal patients — benzodiazepines for agitation, antipsychotics for psychosis — address behavioral management, not suicidal cognition. No medication currently used in standard ER psychiatric protocols has been proven in randomized controlled trials to eradicate suicidal ideation within hours. Intravenous ketamine has. It sits unused in most hospital pharmacies while suicidal patients wait in boarding rooms because no one has built the protocol to administer it.
What Containment Does — and What It Cannot Do
To be precise about what containment does and does not accomplish: a secure inpatient psychiatric unit removes access to lethal means, provides 24-hour monitoring, and allows time for medication adjustment. Those functions save lives. The ASPIRE I and ASPIRE II trials — the two largest esketamine suicide trials ever conducted — inadvertently proved exactly how powerful that environmental effect is: both the active drug group and the placebo group showed large, rapid drops in suicidal thinking at 24 hours, with no statistically significant separation between them on the dedicated suicidality scale. The ward did the work in both arms. Containment is necessary. It is not sufficient. And for the patients who do not have five days to wait for a bed or for medication to work, it is not fast enough.
Where You Are Right Now Determines What You Do Next
Suicidal ideation is not one condition. It has stages. The right move depends on whether the thought is passive, active, or close to action. Do not blur those categories. The difference can decide whether you call a ketamine clinic today, go to the ER now, or tap to call 911 because minutes matter.
If You Might Hurt Yourself Today
If you have a method, a weapon, pills, a location, a timeline, a note, or the feeling that you cannot stop yourself, this is a medical emergency. Do not try to solve it by reading. Do not wait for a clinic callback. Do not stay alone.
Tap to call 988, tap to text 988, tap to chat with 988, go to the nearest ER, or tap to call 911 if you are in immediate danger.
At the ER, say this clearly: “I am having suicidal thoughts and I do not feel safe.” Then ask one direct question: “Does this hospital have a monitored IV ketamine or IM ketamine protocol for acute suicidal ideation?” Most hospitals will not have one. Ask anyway. Make the absence visible in the medical record.
If the Thoughts Are Active but You Do Not Have a Timeline
If you have started thinking about methods, but you do not have a fixed time, place, or immediate intent, you are in the danger zone before an attempt. This is the point where a fast biological circuit breaker matters most. Do not wait for a six-week antidepressant trial to rescue you from a crisis that is moving by the hour.
Call a physician-led IV or IM ketamine clinic today. Use precise language: “I have active suicidal ideation, depression that has not responded to standard treatment, no immediate plan to act today, and I need an urgent medical evaluation for IV or IM ketamine.”
If your intent increases, if you obtain the means, if you pick a time or location, or if you feel unable to stay safe, stop clinic-shopping and go to the ER.
If the Thoughts Are Passive but Relentless
Passive suicidal ideation is not harmless. “I wish I would not wake up,” “I want to disappear,” and “I do not want to live like this” are warning signals, not personality traits. This is the best time to act because you still have enough distance from the thought to make decisions.
Call a physician-led IV or IM ketamine clinic and describe the situation plainly: “I have chronic passive suicidal ideation, no plan, no current intent, and treatment-resistant depression. Can your physician evaluate me for ketamine therapy?”
Do not minimize the words because you are afraid of sounding dramatic. Clinics need accurate risk information. Passive ideation is often the outpatient lane. Active intent is usually the emergency lane. Say exactly where you are.
If You Are Trying to Help Someone Else
Do not argue with the suicidal thought. Do not debate whether their life is worth living. Do not give a speech about gratitude, family, faith, exercise, or tomorrow. Stay concrete.
Say this: “I am not leaving you alone with this. We are going to get medical help now.”
If they have a plan, means, timeline, weapon, pills, or locked-door isolation, treat it as an emergency: tap to call 911 or take them to the ER. If they have passive suicidal thoughts without current intent, call a physician-led IV or IM ketamine clinic and ask for an urgent evaluation. Use the same clinical language every time: suicidal ideation, treatment-resistant depression, no current plan, no immediate intent, urgent evaluation.
If the Person You Love Is Refusing Help
The refusal is not a decision. It is a symptom.
Suicidal ideation generates its own defense system. The same brain state that is producing the desire to die is also producing the arguments against treatment. It will sound like logic. It will sound like your loved one talking. It is not. It is the illness refusing its own cure.
Think of it this way: a person in diabetic shock — brain starved, body failing — will often argue coherently against the glucose injection that will save them. The reasoning sounds intact. The words come out in sentences. But hypoglycemia impairs the judgment of the very brain being asked to approve the treatment. The nurse gives the injection anyway. This is the same situation. The mind generating “I don’t need help” is the mind that needs help. The refusal does not make the danger smaller. It makes it harder to reach.
Your job is not to win an argument. Your job is to stay connected long enough to get one door open.
Why Suicidal People Refuse Help: The Six Most Common Fears — and What to Say
People refuse help for specific reasons. The reason matters because it determines what you say. Generic reassurance (“everything will be okay”) does not reach a specific fear. Naming the fear does.
Fear 1: “They will lock me up and never let me out.”
Fear of involuntary hospitalization is consistently identified in population studies as the most frequently cited barrier to help-seeking among people with active suicidal ideation, outranking cost, distance, and stigma. The image is a locked ward, loss of autonomy, indefinite confinement. It is not accurate, but it is vivid and terrifying, and it is doing real work against you.
Do not promise something you cannot guarantee. Do not say “I promise they won’t hospitalize you.” You do not know that. What you can say is this:
“I hear you. You’re scared about what happens when you ask for help. Here’s what I know: the goal of going is to get your pain treated, not to take your freedom away. We can go together, we can ask questions when we get there, and we can ask what the plan is before anything happens. You don’t disappear into a system. You stay you, and I stay with you.”
If they are at the stage where you are calling a ketamine clinic rather than an ER, the hospitalization fear is even less warranted — and you can be specific: “A ketamine clinic is not a hospital. It is an outpatient medical appointment. You go in, you get evaluated, you go home.” Specificity is the antidote to the catastrophic image in their head.
Fear 2: “Nothing works. I’ve tried everything. This won’t either.”
This is not pessimism. This is the documented cognitive signature of major depression. Hopelessness — the inability to imagine that the future can be different from the present — is a core symptom of major depression, not a rational assessment of one’s actual treatment options. The organ doing the evaluation is the organ that is malfunctioning. Do not argue with it.
Arguing sounds like this: “You haven’t tried everything. You haven’t tried this.” They will have a counter. You will counter back. Thirty minutes will pass and nothing will have moved.
What reaches this fear is not an argument. It is a shift in what you are asking for:
“I’m not asking you to believe it will work. I know you don’t believe that right now and I’m not going to fight you on it. I’m asking you to let a doctor evaluate you. That’s it. You don’t have to hope. You don’t have to feel optimistic. You just have to get in the car.”
You are reducing the ask to its minimum: one physical action, not an emotional commitment. The belief can come later. Right now you need their body in a chair in a clinic or ER.
Fear 3: “I don’t deserve help.”
Shame-based refusal is the quietest and most dangerous kind because it often presents as calm. The person is not combative. They keep saying some version of “I’ll be fine” or “I’m not worth the trouble” or “you should worry about someone who deserves it.” This is not a personal judgment. Thomas Joiner’s interpersonal theory of suicide identifies perceived burdensomeness — the belief that one’s continued existence costs more than it contributes — as one of the two primary psychological drivers of suicidal desire. The feeling of not deserving help is a symptom of the same mechanism generating the suicidal thinking.
Do not counter this with a list of their virtues. Do not give the speech about how much they mean to you. That argument lands in a brain that has already decided it is not worth hearing. It bounces off.
What cuts through shame is a factual reframe that removes their self-judgment from the equation entirely:
“I’m not asking you to agree that you deserve help. This isn’t about whether you deserve it. A broken leg doesn’t have to earn treatment. Your brain is in a medical state right now and the doctor doesn’t need you to feel worthy of being treated. We’re not asking your opinion about your own value. We’re calling a doctor because that’s what you do when something is medically wrong.”
Shame is an argument. Medicine is not.
Fear 4: “You don’t understand. No one can understand.”
This is a withdrawal signal. It is the person beginning to close off the connection between themselves and everyone who could help them. It is not rudeness. It is the illness narrowing their world down to a point.
The instinct is to prove that you do understand — to offer evidence of empathy, to meet them emotionally. The problem is that any sentence beginning with “I understand how you feel” is immediately testable and immediately deniable. They will tell you that you don’t, and they will be partly right, and now the conversation is about you instead of about them.
What works is staying present without trying to win:
“You’re right. I don’t know exactly what this feels like from inside it. I’m not going to pretend I do. But I know that you’re suffering and I know that I’m not going to leave. You don’t have to feel understood right now. You just have to let me sit here with you while we figure out the next step together.”
This response does not claim understanding it cannot have. It claims presence, which it can deliver. Stay physically close. Do not leave them alone. Social connectedness and a sustained sense of belonging are among the most robustly documented protective factors against suicidal behavior in the clinical literature. The connection itself is doing medical work even when no words are landing.
Fear 5: “I just need to sleep. I’ll feel better tomorrow.”
Minimization is often the last defense before someone agrees to help — which means it can look like resolution when it is not. The person seems calmer, more reasonable. They have a plan: sleep. The urgency feels like it has passed.
It has not passed. Minimization is the illness buying time.
Do not accept a delay without a concrete next step attached to it:
“Okay. Here is what I want to do: I’m going to stay here tonight. And tomorrow morning — not next week, tomorrow morning — we are calling a clinic together. I’m going to be here when you wake up and I’m going to make that call with you. If you feel worse before morning, we’re not waiting. But I need you to agree that tomorrow morning happens.”
You are not arguing. You are narrowing the timeline. “Tomorrow morning” is specific enough to foreclose indefinite delay. “I’m staying here” removes the isolation that makes the night dangerous. If they will not agree to a specific next step, that is information. Treat it as escalation, not resolution.
Fear 6: The Locked Door
This is no longer a conversation about persuasion. A locked door with a suicidal person behind it — not responding, or responding in ways that suggest immediate danger — is a medical emergency.
You do not talk someone through a locked door to safety by finding the right words. The door needs to be opened.
If they are responding through the door and their words suggest passive ideation without immediate plan or means, stay talking. Keep your voice calm and continuous. A person in contact with a caring presence — even through a barrier — remains socially connected, and sustained social connection is a documented brake on suicidal crisis escalation. Disconnection is more dangerous than the door.
Say this:
“I’m not going anywhere. I’m right here. I’m not calling anyone yet, I’m just here. Can you tell me what’s happening in there? I’m listening.”
If they stop responding, if their words suggest a plan, means, or action in progress, or if you hear sounds that suggest self-harm is occurring: call 911 now. Say this when the call connects:
“My [family member] is locked in a room and is suicidal and I am unable to reach them. I need a wellness check. Please send officers who are trained in mental health crisis response if your department has them.”
Crisis Intervention Team training prepares law enforcement officers specifically for psychiatric emergencies — and in many cities, dispatchers can flag a call for CIT-trained officers or co-responder teams pairing a clinician with a patrol officer. That distinction can change how they arrive and how they communicate. Make the request out loud so it is on the dispatch record.
What You Must Never Say
These are the responses that feel like they should help and do not:
“Think about how this would affect me / the children / your mother.” This loads the person in crisis with guilt they cannot process and that the illness will weaponize. Perceived burdensomeness — the felt certainty that one is a net cost to the people who love them — is already one of the two core psychological states driving suicidal desire according to Joiner’s interpersonal theory. Reminding someone in that state of the suffering their death would cause does not interrupt the crisis. It can deepen it.
“I promise I won’t call anyone.” Do not make this promise. You cannot keep it if their life requires you to break it. A promise you cannot keep destroys the only bridge you have at the moment it matters most. Say this instead:
“I’m not going to do anything without telling you first, unless I believe you are in immediate danger. If it gets to that point, I will tell you before I call.”
“You seemed fine yesterday.” Suicidal crises do not follow emotional logic that observers outside the crisis can track. This statement tells the person in crisis that their experience is not legible, not credible, or exaggerated. It closes the door.
“I need you to promise me you won’t hurt yourself.” No-suicide contracts and verbal safety promises extracted during a crisis episode have no demonstrated efficacy as safety interventions and have been specifically argued against in the peer-reviewed literature because they shift responsibility to the person least equipped to carry it. Do not ask for the promise. Ask for the next concrete physical action.
Anything that starts with “At least.” “At least you have a job.” “At least you have a family.” The “at least” construction tells the person that their pain requires context before it qualifies for treatment. The pain is the emergency. It does not need context. It needs a medical intervention.
When to Call 911 Against Their Wishes
You are allowed to do this. You do not need their permission to save their life.
The threshold is not “they are upset with me” or “they told me not to.” The threshold is danger. The American Foundation for Suicide Prevention identifies the following as warning signs requiring immediate action. Call 911 when:
- They have a method available right now — pills, a weapon, a means — and have communicated intent to use it, or you have reason to believe they intend to act.
- They have stopped responding and you cannot verify their physical safety.
- They have given away significant possessions, said goodbye in a way that felt final, or written or shown you a note.
- They have told you — at any point recently — that they have a plan, a time, a place, or that they are going to do it.
- You cannot reach them and you know they are alone.
If any of these are true and you are asking yourself “but what if I’m wrong” — you are not wrong enough for that calculation to matter. A wellness check that turns out to be unnecessary costs embarrassment. Not calling costs everything. The math is not close.
“My [family member] is suicidal and I believe they are in immediate danger. I need a wellness check. Please send officers trained in mental health crisis response if available. They do not have weapons. They are not violent. This is a psychiatric emergency.”
Framing the call as psychiatric — not violent, not criminal — gives responding officers information that can change how they approach the scene, particularly in departments with Crisis Intervention Team-trained officers or co-responder programs pairing law enforcement with a mental health clinician. Make the framing out loud so it is captured in the dispatch record.
After They Get Help: They May Be Angry. That Is the Right Outcome.
A person who survives a suicidal crisis and is angry at you for calling for help is a person who survived. That is the only outcome that matters right now.
The anger will probably be real. “You betrayed me.” “I never asked for this.” “You had no right.” These are normal responses to having autonomy overridden at a moment of extreme psychological distress. They do not mean you were wrong. They mean the person is alive enough to be angry.
Do not demand gratitude. Do not defend yourself at length. Do not withdraw because the response is painful.
“I know you’re angry. I’m glad you’re here to be angry at me. When you’re ready to talk, I’ll be here.”
Then be there. The repair comes after the crisis. The crisis comes first.
Which Ketamine Treatment Has the Best Proof for Suicidal Thoughts?
IV ketamine has the strongest suicide-specific trial record. IM ketamine has the strongest emergency-room deployment case. Spravato is a nasal esketamine product for depression symptoms, but it has not proven that it prevents suicide or directly reduces suicidal ideation or behavior.
Do not treat these as equal options. They are different drugs, different routes, different blood levels, different protocols, and different evidence records. If the question is “What has the strongest proof for rapidly clearing suicidal thoughts?” the answer is IV ketamine.
IV Ketamine Has the Strongest Proof Because It Beat Control Treatments on Suicidal Thoughts
IV racemic ketamine is the lead treatment in this page because it has the best suicide-specific data. It has been tested in randomized trials, placebo-controlled trials, and active-control trials using midazolam. It has shown rapid reductions on suicide-specific measures, not just general depression scales.
In an emergency-department randomized trial, 88% of acutely suicidal patients who received IV ketamine reached remission from suicidal ideation within three hours, compared with 33% who received placebo. That is not a mood-score footnote. That is suicidal ideation remission measured inside an emergency setting.
In a multicenter hospital trial of patients with severe suicidal ideation, 63% of patients who received IV ketamine reached full remission by Day 3, compared with 31.6% who received standard care plus placebo. Both groups were hospitalized. Both groups received psychiatric care. The ketamine group still doubled the remission rate.
In a midazolam-controlled randomized clinical trial, IV ketamine reduced suicidal ideation by 4.96 more points than midazolam at 24 hours. The same trial found that 55% of patients receiving ketamine had at least a 50% drop in suicidal ideation by Day 1, compared with 30% receiving midazolam.
The practical conclusion is simple: IV ketamine is the treatment with the clearest human trial evidence for fast suicidal-thought relief. It is the option families should know about first. It is the option hospitals should have built into suicide-crisis protocols years ago.
IM Ketamine Is the Practical ER Option Because It Avoids the IV Bottleneck
IM ketamine does not have the same level of proof as IV ketamine. The weakness is specific: fewer studies, smaller patient pools, less blinding, and no completed large emergency-department randomized trial proving the same effect size as IV.
But IM ketamine solves a hospital logistics problem that IV ketamine creates. It does not require IV placement, an infusion pump, or the staffing needed to run and monitor a 40-minute IV infusion. A clinician can give it as an injection, monitor blood pressure, pulse oximetry, sedation, and dissociation, and move faster in settings where IV access slows everything down.
In a prospective interventional study of acutely suicidal patients, a single 0.5 mg/kg IM ketamine injection cut suicide scores by 78% within two hours. The same study found that 76% of patients reported complete clearance of suicidal thoughts within two hours. At one month, 89% maintained the reduction in suicidal ideation, and 64% stayed stable after one injection.
A psychiatric emergency-department trial-design paper states the operational problem directly: most ketamine suicide studies used 40-minute IV infusions, which can be impractical in a psychiatric emergency department. That is why IM ketamine matters. It could put a fast-acting anti-suicidal intervention into ERs, crisis units, rural hospitals, and low-resource clinics that will never build a full infusion service.
The IM conclusion is narrower than the IV conclusion: the early numbers are strong enough to justify hospital protocols and large randomized trials now. The evidence is not strong enough to rank IM above IV. IV has the trial record. IM has the deployment advantage.
Spravato Does Not Come Close to IV Ketamine for Suicide-Specific Relief
Spravato is not the treatment this page is fighting for in emergency suicide care. It is intranasal esketamine, not IV racemic ketamine. It is delivered through a REMS-certified clinic protocol, not an emergency-room IV or IM suicide-crisis protocol. Its strongest evidence is rapid depression-symptom reduction, not direct clearance of suicidal ideation.
The FDA label makes the limit explicit: Spravato’s effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated.
The trial record matches that warning. In ASPIRE I, Spravato improved depression scores at 24 hours but did not produce a separate statistically proven advantage on the clinical suicidality severity scale. In ASPIRE II, Spravato improved depression symptoms within 24 hours, but suicide-specific scores dropped sharply in both the Spravato group and the placebo group. Hospitalization, observation, medication changes, and crisis containment lowered suicide scores in both groups, leaving no clear suicide-specific drug victory at 24 hours.
The adolescent trial showed the same split. Esketamine beat midazolam on depression scores at 24 hours, while suicidality scores improved across all treatment groups without a separate suicide-scale win.
That is the plain-language verdict: Spravato can reduce depression symptoms quickly. It has not proven what IV ketamine has proven in suicide-specific trials. It should not be sold to a suicidal reader as equivalent to IV ketamine. It is not equivalent.
The Practical Ranking for a Suicidal Person or Family
| Treatment | What it has proven best | What it has not proven | Plain verdict |
|---|---|---|---|
| IV racemic ketamine | Rapid reduction and remission of suicidal ideation in controlled trials | Permanent protection from relapse after one infusion | Best-supported option for fast suicidal-thought relief |
| IM racemic ketamine | Fast suicidal-thought reduction in smaller early studies; easier emergency deployment than IV | Same level of proof as IV ketamine | Most practical ER candidate, but needs larger blinded trials |
| Spravato/esketamine nasal spray | Rapid depression-symptom improvement under REMS monitoring | Prevention of suicide or direct reduction of suicidal ideation or behavior | Not equivalent to IV ketamine for suicidal thoughts |
The order is not subtle: IV first for proof, IM first for emergency-room practicality, Spravato third for this specific problem. If the target is rapid relief from suicidal thoughts, do not let anyone collapse these treatments into the same category.
Why Emergency Rooms Lock Patients Down But Won’t Give Them Ketamine
If you might act today, go to the ER or tap to call 911. If you are trying to protect someone who has a weapon, pills, a plan, a timeline, a suicide note, or a locked door between you and them, call 911 or take them to the ER now. The ER is still the right place when immediate physical safety is the problem.
But most ERs will not give IV or IM ketamine for suicidal ideation. They will usually search the patient, remove dangerous objects, assign observation, order medical screening, request a psychiatric evaluation, and wait for admission, transfer, or discharge planning.
Those steps reduce the chance that the patient dies inside the hospital. They do not deliver the fastest suicide-specific treatment discussed on this page.
The ER Knows Ketamine. It Usually Does Not Use It for Suicidal Ideation.
Emergency physicians already use ketamine. They use it for procedural sedation, severe agitation, and pain protocols. ACEP has published emergency-department ketamine guidance for sedation and low-dose analgesia, and ACEP psychiatric-patient guidance lists ketamine as an option for immediate sedation of a severely agitated, violent, or aggressive patient.
That is not the same as using ketamine to treat suicidal ideation.
In most ERs, ketamine is a sedation drug or pain drug. It is not a standing suicide-crisis treatment. A suicidal patient who is calm, coherent, and asking for help will usually enter the psychiatric-risk pathway, not a ketamine-treatment pathway.
Why Most ERs Still Do Not Offer It
The failure has several causes.
First, suicide care in the ER was built around containment before ketamine’s rapid anti-suicidal data existed. The default workflow is identify risk, remove means, watch the patient, get psychiatric input, and find the safest disposition. That workflow can prevent an attempt during the ER stay. It was not designed to clear suicidal ideation within hours.
Second, IV ketamine for suicidal ideation is still not a standard ER order set in most hospitals. A protocol requires inclusion criteria, exclusion criteria, consent language, dosing rules, blood-pressure thresholds, monitoring intervals, staffing assignments, rescue medication rules, discharge criteria, and follow-up scheduling. Without that written protocol, an ER doctor cannot simply decide to improvise ketamine for a suicidal patient while the department is full.
Third, ketamine’s psychiatric use sits between departments. Emergency medicine controls the ER. Psychiatry controls suicide-risk assessment and inpatient placement. Anesthesia often controls hospital comfort with ketamine infusion practices. Pharmacy controls medication policy. Risk management controls liability exposure. If no department owns the protocol, the protocol does not exist.
Fourth, hospitals know ketamine’s antidepressant role better than its suicide-specific role. Spravato advertising, REMS clinics, and treatment-resistant-depression programs made ketamine visible as a depression treatment. Fewer hospital systems have translated the suicide-specific IV and IM data into an ER protocol for patients who arrive saying they may die.
Fifth, psychiatric boarding turns suicidal ideation into a placement problem. ACEP reports that 62% of emergency-department directors said they had no psychiatric services for psychiatric patients boarding in the ER. If an ER cannot provide psychiatric treatment to boarded patients, it is even less likely to run a monitored ketamine protocol for suicidal ideation.
The Result: The Patient Gets Watched While the Suicidal Thoughts Continue
A suicidal patient may spend hours in a monitored room with no belt, no phone charger cord, no bag, no medications, no privacy, and no ability to leave. That can stop an immediate attempt. It does not necessarily stop the thought, “I still want to die.”
If the patient is agitated, intoxicated, psychotic, or violent, staff may use sedatives, antipsychotics, restraints, or seclusion. Those interventions can reduce danger to the patient and staff. They do not equal IV or IM ketamine treatment for suicidal ideation.
The missing action is specific: a physician order for monitored IV or IM ketamine after the patient meets suicide-risk, medical-safety, blood-pressure, psychosis, mania, substance-use, and consent criteria.
Ask About Ketamine When the Patient Enters the ER
Ask early. Do not wait until discharge.
Say this to the attending physician or charge nurse: “Does this hospital have a monitored IV ketamine or IM ketamine protocol for acute suicidal ideation?”
If they say no, ask this: “Who in this hospital is responsible for deciding whether suicidal patients can receive IV or IM ketamine — emergency medicine, psychiatry, anesthesia, pharmacy, or risk management?”
Then hand them printed studies from the evidence section at the bottom of this page. Use the printed studies as proof, not as a debate tactic. Say: “These are the studies we are asking you to review. We are asking whether this hospital has a protocol for this treatment.”
If the hospital has no protocol, ask for the answer in the chart: “Please document that we asked whether the hospital offers monitored IV or IM ketamine for acute suicidal ideation and were told it does not.”
That chart note will not force the ER to give ketamine that day. It creates a written record that the family asked for a rapid anti-suicidal treatment and the hospital had no protocol. Repeated records can reach the people who can change the system: emergency-medicine chiefs, psychiatry chairs, pharmacy committees, risk managers, hospital administrators, and quality-improvement boards.
Use the ER first when the person cannot stay safe. Once the person is searched, watched, and physically protected, ask why the hospital is not offering IV or IM ketamine for the suicidal ideation that brought them there.
What an ER Ketamine Protocol for Suicidal Ideation Would Require
A hospital ketamine protocol is not a doctor saying, “Ketamine sounds reasonable.” It is a written pathway for suicidal patients who have been medically screened, physically protected, and cleared for monitored ketamine treatment.
The pathway has to answer concrete questions before the patient arrives: which suicidal patients qualify, which patients are excluded, which ketamine route the hospital uses, who writes the order, who monitors the patient, what vital signs stop treatment, and who owns follow-up after discharge.
Hospitals already build written pathways for stroke, sepsis, chest pain, alcohol withdrawal, opioid overdose, and violent agitation. Suicidal ideation needs the same machinery: criteria, orders, monitoring, documentation, escalation rules, and follow-up.
Which Suicidal Patients Could Qualify for Hospital Ketamine?
The target patient is not every depressed person. The target patient is someone who comes to the ER with suicidal ideation and needs rapid medical intervention after immediate physical safety is secured.
An eligible patient has been medically screened, is physically safe under observation, has no untreated overdose, has no unstable medical emergency, and has blood pressure, pulse, oxygen status, and breathing inside the hospital’s treatment limits.
The patient must also be clinically appropriate for ketamine that day. That means no acute psychosis, no active mania, no severe intoxication blocking consent, no uncontrolled medical instability, and no condition the hospital protocol lists as a ketamine exclusion.
Eligibility should also require a suicide-specific baseline measure before treatment. The hospital should document the patient’s suicidal ideation before ketamine, after ketamine, before discharge, and at follow-up. Without that tracking, the hospital cannot tell whether ketamine reduced suicidal ideation or merely sedated the patient.
Which Suicidal Patients Should Be Excluded or Stabilized First?
A suicide-crisis ketamine protocol must name the patients who should not receive ketamine until another danger is handled first.
A patient with an untreated overdose needs overdose treatment first. A patient with uncontrolled blood pressure needs blood-pressure control first. A patient with unstable chest pain, dangerous arrhythmia, severe respiratory compromise, or loss of consciousness needs medical stabilization first.
A patient with active psychosis or mania needs psychiatric stabilization before ketamine unless the hospital protocol creates a specific exception approved by psychiatry, emergency medicine, and risk management.
A patient too intoxicated, delirious, or cognitively impaired to participate in consent needs a separate consent pathway or a delay until the patient can be evaluated safely.
These exclusions do not weaken the case for ketamine. They make the protocol usable. A hospital cannot build suicide-crisis ketamine care by improvising around overdose, mania, psychosis, blood-pressure spikes, or consent problems at the bedside.
IV Ketamine or IM Ketamine: The Hospital Must Pick the Route Before the Patient Arrives
The hospital must decide before the crisis starts which ketamine route its protocol allows.
One hospital might approve IV ketamine only. That pathway fits patients who can receive IV placement, infusion equipment, nursing coverage, blood-pressure checks, pulse oximetry, mental-status checks, and post-dose observation.
In the BMJ severe-suicidal-ideation trial, patients received two 40-minute IV ketamine infusions at 0.5 mg/kg, given at baseline and 24 hours. That is an IV infusion protocol, not a quick injection protocol.
Another hospital might approve IM ketamine for selected emergency cases where IV access, infusion pumps, or infusion staffing would delay treatment. That pathway fits suicidal patients who meet the same psychiatric and medical criteria but need an injection-based route.
A larger hospital could build two separate pathways: one for IV ketamine and one for IM ketamine. The patient receives one route under one protocol. They do not receive IV and IM ketamine together.
The Ketamine Order Set Has to Be Written Before the Crisis
The order set must tell the clinician what to order without guesswork.
It should specify route, dose range, maximum dose, infusion or injection timing, baseline vital signs, blood-pressure stop rules, pulse oximetry, sedation checks, dissociation checks, nausea treatment, rescue medication rules, fall precautions, and minimum post-dose observation time.
It should also specify who can order ketamine: an emergency physician, psychiatrist, anesthesiologist, critical-care physician, or another credentialed clinician approved by the hospital.
Without an order set, the suicidal patient gets whatever the hospital already has: search, observation, medical clearance, psychiatric evaluation, and boarding. The ketamine evidence never reaches the bedside because no one has authority to order it.
Monitoring Cannot Be Optional
Ketamine for suicidal ideation requires monitored medical care. The protocol must state who checks blood pressure, who watches breathing, who tracks sedation, who evaluates dissociation, who manages vomiting or panic, and who decides whether the patient is safe to leave the treatment area.
Spravato clinics already prove that monitored psychiatric ketamine care can operate in routine practice. The Spravato REMS program requires at least two hours of post-dose observation for sedation, dissociation, respiratory depression, and vital-sign changes.
IV and IM ketamine for suicidal ideation need hospital-specific rules, not a copy of Spravato REMS. But the basic point is already settled: monitored ketamine workflows exist in American psychiatric care. Hospitals need an ER version for suicidal ideation.
Psychiatry, Emergency Medicine, Pharmacy, and Risk Management All Have to Own a Piece
A ketamine protocol dies if every department assumes another department owns it.
Emergency medicine should own triage, medical screening, airway readiness, vital-sign monitoring, and immediate safety.
Psychiatry should own suicide-risk assessment, diagnosis, consent capacity, post-treatment evaluation, disposition, and follow-up planning.
Pharmacy should own medication storage, preparation, dosing limits, contraindication alerts, controlled-substance documentation, and medication-interaction checks.
Anesthesia, critical care, or another hospital monitoring authority should define escalation rules for blood pressure, respiratory problems, severe sedation, or severe dissociation.
Risk management should approve consent language, documentation requirements, charting language, and adverse-event review.
If no department owns the protocol, the suicidal patient gets observation instead of ketamine.
Follow-Up Has to Be Scheduled Before Discharge
A hospital ketamine protocol cannot end when the suicidal thoughts drop. A single dose can reduce suicidal ideation fast. It does not guarantee protection after discharge.
The discharge plan should be written before the patient leaves the ER or inpatient unit. It should include a next-day contact, a scheduled psychiatry appointment, a decision about ketamine continuation, a therapy referral, medication review, lethal-means restriction, family contact instructions, and return-to-ER instructions if suicidal intent returns.
The hospital should not give ketamine for suicidal ideation and then discharge the patient with “follow up outpatient.” The protocol has to connect fast relief to the next 24 hours, the next week, and the next treatment step.
What Families Should Ask the Hospital
Do not ask the ER doctor to improvise ketamine outside hospital policy. Ask whether the hospital has a policy.
Use this wording: “Does this hospital have a written IV or IM ketamine protocol for acute suicidal ideation, including eligibility criteria, exclusion criteria, monitoring rules, suicide-scale tracking, and follow-up before discharge?”
If the answer is no, hand the physician printed studies from the evidence section at the bottom of this page.
Say: “These are the studies we are asking you to review. We are asking whether this hospital has a protocol for IV or IM ketamine for suicidal ideation.”
Then ask for the answer in the chart:
“Please document that we asked whether the hospital offers monitored IV or IM ketamine for acute suicidal ideation and were told it does not.”
The demand is not bedside experimentation. The demand is a written hospital pathway for a fast anti-suicidal treatment that outpatient ketamine clinics already know how to monitor and that most ERs still do not offer to suicidal patients.
Ketamine’s Effect on Suicidal Ideation: Every Study We Found From the Last 10 Years
We looked for every study published in the last 10 years that measured ketamine’s effect on suicidal ideation. We separated the evidence by route because intravenous ketamine, ketamine injections, and Spravato nasal spray do not have the same results.
Intravenous ketamine has the strongest human trial record for reducing or clearing suicidal thoughts within hours. Ketamine injections have fewer controlled studies, but the early data show fast suicidal-thought reduction without the 40-minute infusion barrier. Spravato nasal spray can reduce depression symptoms quickly, but large trials did not prove the same direct suicide-specific effect shown in the intravenous ketamine studies.
Each card gives the study name, year, study type, and finding. The point is to show what each treatment actually proved, how fast it worked, and where the evidence is strong, weak, or unfinished.
Intravenous Ketamine Studies
Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine
2016 · Intravenous ketamine · Open-label repeated-dose study · 14 patients
Patients received 6 infusions over 3 weeks. Half reached full remission from suicidal ideation during active treatment, and 29% of remitters kept full resolution through 3 months. The weakness is clear: no control group and only 14 patients.
Efficacy of an Adjunctive Ketamine Infusion on Suicidal Ideation in Treatment-Resistant Depression
2017 · Intravenous ketamine · Double-blind randomized midazolam-controlled trial · 36 patients
A single 0.5 mg/kg ketamine infusion reduced suicidal ideation more than midazolam within 24 hours. The advantage remained through Day 6. This matters because midazolam is an active psychoactive control, not an inert placebo.
Effects of Ketamine on Suicidal Ideation
2018 · Intravenous ketamine · Individual patient data meta-analysis · 167 patients from 10 trials
A single ketamine dose reduced suicidal ideation within 24 hours, with effect sizes from 0.48 to 0.85. The benefit remained after adjusting for depression improvement, which means ketamine’s anti-suicidal effect was not just a byproduct of mood improvement. The effect lasted up to 7 days.
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression
2018 · Intravenous ketamine · Double-blind randomized midazolam-controlled trial · 80 patients
Ketamine reduced suicidal ideation by 4.96 more points than midazolam at 24 hours. At Day 1, 55% of ketamine patients had at least a 50% drop in suicidal ideation, compared with 30% receiving midazolam. Differences emerged at 230 minutes and held at 24 hours.
Single and Repeated Ketamine Infusions for Reduction of Suicidal Ideation in Treatment-Resistant Depression
2020 · Intravenous ketamine · Double-blind randomized crossover trial with open-label maintenance · 37 patients
A single ketamine infusion reduced suicidal ideation more than midazolam, with maximum effect at 7 days. Repeated infusions produced cumulative reductions. After repeated treatment, 69% of participants had complete alleviation of suicidal ideation, and once-weekly maintenance infusions prolonged stability.
Subanesthetic Ketamine Infusion for the Treatment of Acute Suicidal Ideation in the Emergency Department
2020 · Intravenous ketamine · Double-blind randomized placebo-controlled emergency-department pilot · 18 patients
A single ketamine infusion produced remission from suicidal ideation in 88% of acutely suicidal emergency-department patients within 3 hours, compared with 33% receiving placebo. Separation appeared early and held from 90 through 180 minutes. The weakness is the small pilot sample.
Ketamine for the Acute Treatment of Severe Suicidal Ideation
2022 · Intravenous ketamine · Multicenter double-blind randomized placebo-controlled trial · 156 patients
By Day 3, 63.0% of ketamine patients reached full remission from severe suicidal ideation, compared with 31.6% receiving standard care plus placebo. Both groups were hospitalized. Ketamine doubled remission inside the same hospital safety setting. Over 6 weeks after discharge, suicide-attempt rates did not differ significantly.
Plasma VEGF Concentrations and Ketamine’s Effects on Suicidal Ideation in Depression With Suicidal Ideation
2022 · Intravenous ketamine · Open-label repeated-dose interventional trial · 60 patients
Anti-suicidal response rates were 61.7% at Day 1, 81.7% at Day 13, and 73.3% at Day 26. The study found no relationship between plasma VEGF changes and suicide-score improvement. The weakness is no randomized control group.
Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample
2022 · Intravenous ketamine · Retrospective multi-site cohort study · 424 patients
Repeated ketamine infusions cut self-harm and suicidal-ideation symptom scores by 50% within 6 weeks. Exactly 50% of patients with active suicidal ideation at baseline had complete resolution after the primary 6-infusion stabilization block. The weakness is major: observational chart review, no randomization, no blinding, and no control arm.
Is Ketamine Efficacious for Rapid Treatment of Acute Suicidal Ideation in an Emergency Setting?
2023 · Intravenous ketamine · Double-blind randomized emergency pilot trial · 36 patients
Ketamine reduced severe suicidal ideation at 12 and 24 hours, but it did not beat midazolam by a statistically clear margin. The likely reason is the hospital effect: both groups entered acute psychiatric stabilization, and both groups improved rapidly. This is a mixed result, not a clean ketamine win.
Repeated Ketamine Infusions for Unipolar Depression With Suicidal Ideation in Adolescents
2023 · Intravenous ketamine · Randomized double-blind placebo-controlled trial · 94 adolescents
Repeated intravenous ketamine produced rapid suicidal-ideation reduction in adolescents ages 13 to 17 with major depression and severe active suicidal thoughts. The anti-suicidal difference was established 24 hours after the first active infusion. The study found no acute or persistent deficits in processing speed, verbal memory, visual learning, or executive function.
Repeated Ketamine Infusions on Suicidal Ideation in Unipolar and Bipolar Depression
2023 · Intravenous ketamine · Double-blind randomized placebo-controlled trial · 90 patients
Repeated ketamine infusions reduced suicidal ideation in both unipolar and bipolar depression. The ketamine group separated from placebo within 24 hours of the second infusion, and reductions continued through Day 14. Bipolar diagnosis did not reduce or delay the acute anti-suicidal response.
Low-Dose Ketamine Infusion in Treatment-Resistant Depression With Prominent Suicidal Ideation
2023 · Intravenous ketamine · Randomized double-blind active-controlled trial · 84 patients
A single low-dose ketamine infusion reduced suicidal thoughts within 24 hours, with follow-up through 2 weeks. The response was weaker in patients with severe chronic treatment resistance. This study matters because it names a likely failure point: patients with deeper long-term treatment resistance may respond less strongly.
Early Response to Ketamine for Suicidal Crisis Reduces Suicidal Events at 3 Months
2025 · Intravenous ketamine · Retrospective observational cohort study · 100 patients
Patients who had an early anti-suicidal response within 7 days of starting ketamine had 75% lower odds of suicide attempts or acute hospitalizations for suicide risk over 3 months. Exactly 61% met early-response criteria, defined as at least a 50% drop in suicide-scale severity. The weakness is observational design, not randomized proof.
Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality
2025 · Intravenous ketamine · Systematic review and meta-analysis of randomized trials · 649 patients
Across 10 randomized trials, ketamine reduced suicidal ideation more than midazolam, with mean differences of -1.23 points on MADRS suicidal-ideation scoring and -4.30 points on the Beck Scale for Suicide Ideation. Ketamine also reduced depression severity by -6.23 points on the MADRS. Superiority on suicide measures was established within 24 hours.
Anti-Suicidal Effects of Lithium, Ketamine, and Clozapine
2025 · Intravenous ketamine · 10-year systematic literature review · 1,420 pooled high-risk patients
Ketamine showed rapid short-term reduction in acute suicidal ideation within 1 to 4 hours, with peak anti-suicidal effect at 24 hours and effects lasting up to 1 week. The review distinguishes ketamine from lithium and clozapine: lithium and clozapine work as long-term suicide-risk reducers, while ketamine works as a rapid crisis intervention. Long-term repeated-dose benefit remained inconsistent.
Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder
2026 · Intravenous ketamine followed by buprenorphine · Outpatient double-blind randomized trial · 45 analyzed patients
Ketamine produced the first drop in suicidal ideation within 24 hours. Adding 4 weeks of low-dose daily sublingual buprenorphine extended the effect: at Day 31, 78% of the ketamine-plus-buprenorphine group remained full anti-suicidal responders, compared with 48% in the ketamine-plus-placebo group. Average suicide-scale scores were 3.6 with buprenorphine versus 8.7 with placebo.
Ketamine vs. Electroconvulsive Therapy in Severe Depression With Suicidal Ideation
2026 · Intravenous ketamine · Randomized controlled trial · 64 patients
Both ketamine and electroconvulsive therapy sharply reduced suicidal ideation by week 4. Ketamine acted faster during the first two treatment sessions. Suicide-scale scores fell from 12.6 to 2.0 with ketamine and from 12.1 to 1.2 with electroconvulsive therapy by week 4. Electroconvulsive therapy showed slightly stronger final durability but caused transient cognitive deficits.
Single and Repeated Ketamine Infusions for Reduction of Suicidal Ideation in Major Depressive Episodes
2026 · Intravenous ketamine · Systematic review and meta-analysis of randomized trials · 1,166 patients
A single ketamine infusion reduced suicidal symptoms more than control treatments at 24 hours, with an effect size of -0.69, and remained superior at 1 month, with an effect size of -0.70. Repeated infusions also reduced suicidal symptoms at the end of treatment, with an effect size of -0.72. The review flags functional unblinding as a limitation because many patients can tell when they received ketamine.
Ketamine Injection Studies
Subcutaneous Ketamine in the Treatment of Depression and Suicide Risk
2023 · Subcutaneous ketamine injection · Case report · 1 patient
One patient with major depression after a life-threatening suicide attempt had complete remission across depression, anxiety, and suicide measures after 3 subcutaneous ketamine sessions spaced 48 hours apart. Suicidal cognition remitted within 48 hours of the second injection. The evidence level is very low because this is a single-patient case report.
Subcutaneous Ketamine Reduces Suicide Risk and Improves Functioning in Depression
2024 · Subcutaneous ketamine injection · Naturalistic prospective open-label cohort · 26 patients
Repeated subcutaneous ketamine reduced suicidal ideation in adults with severe active suicidal thoughts. Most patients reached complete remission after about 8 sessions. Benefits were sustained over 6 months, and higher doses correlated with larger suicidal-ideation reductions. The weakness is no randomized control group.
Intramuscular Ketamine vs. Midazolam for Rapid Risk-Reduction in Suicidal, Depressed Emergency Patients
2024 · Intramuscular ketamine injection · Emergency-department trial design and feasibility report · 53 randomized at reporting, target 90
This paper explains why intramuscular ketamine matters in emergency departments: it avoids IV access, infusion pumps, and a 40-minute infusion. Preliminary pharmacokinetic and safety data showed IV-level bioavailability within 5 minutes and no cardiorespiratory suppression. This is not final efficacy proof; it is feasibility and protocol evidence from an ongoing trial.
Intramuscular Ketamine for Suicidal Ideation in a Tertiary Care Hospital
2025 · Intramuscular ketamine injection · Open-label prospective interventional trial · 38 patients
A single 0.5 mg/kg intramuscular ketamine injection cut suicide scores by 78% within 2 hours. Complete clearance of suicidal thoughts occurred in 76% of patients, equal to 29 of 38. At 1 month, 89% maintained the reduction, and 64% stayed stable after one injection. The weakness is no blinding, no randomization, and no control arm.
Spravato Nasal Spray and Esketamine Studies
Intranasal Esketamine for Rapid Reduction of Depression and Suicidality in Patients at Imminent Risk for Suicide
2018 · Esketamine nasal spray · Phase 2a double-blind randomized placebo-controlled trial · 68 patients
Esketamine produced a stronger improvement on a suicidal-thought item at 4 hours, with an effect size of 0.67. The effect shrank to 0.35 at 24 hours and 0.29 at Day 25. Clinical suicide-risk judgment did not separate at 24 hours or Day 25. Hospitalization and standard care improved both groups.
Esketamine Nasal Spray for Active Suicidal Ideation With Intent: ASPIRE I
2020 · Spravato nasal spray · Multicenter double-blind Phase 3 randomized trial · 226 patients
Spravato met the depression-symptom endpoint at 24 hours. It did not produce a separate statistically proven advantage on the clinical suicidality severity scale. The suicidal-thought item improved at 4 hours but not at 24 hours. Both groups improved rapidly after emergency hospitalization and intensive standard care.
Esketamine Nasal Spray for Active Suicidal Ideation With Intent: ASPIRE II
2021 · Spravato nasal spray · Multicenter double-blind Phase 3 randomized trial · 230 patients
Spravato improved depression symptoms within 24 hours. Suicide-specific scores dropped sharply in both the Spravato and placebo groups, with no clear drug-specific suicide advantage at 24 hours. Full clinical remission at 24 hours occurred in 22% of the Spravato group versus 11% of the placebo group.
Esketamine Nasal Spray for Major Depression With Acute Suicidal Ideation or Behavior
2021 · Spravato nasal spray · Pooled post hoc analysis of ASPIRE I and II · 456 patients
The pooled analysis found rapid depression-symptom improvement, but the full-cohort difference on the clinical suicidality scale at 24 hours was -0.20 and missed standalone statistical significance. A pre-specified subgroup with a history of prior suicide attempts showed a stronger 24-hour suicidality difference of -0.31. This result is narrower than a general anti-suicidal claim for all patients.
Esketamine in Severe Depression and Suicidal Ideation
2023 · Spravato nasal spray · Systematic review and meta-analysis · 522 pooled patients
Esketamine reduced depression scores more than placebo at 24 hours, with a standardized mean difference of -3.18. It produced a 12% absolute increase in clinical remission at Day 25. Suicide-specific scores dropped similarly in both arms, so the review did not show a separate Spravato advantage for suicidal ideation over hospitalization and standard care.
Esketamine Treatment for Depression in Adults
2024 · Spravato nasal spray · PRISMA systematic review and meta-analysis · 87 extracted datasets
Across pooled randomized trials, esketamine did not show statistically significant standalone efficacy against suicidality at any time point. The depression effect was modest in treatment-resistant populations. On suicide-specific instruments, active treatment blocks at weeks 2 to 4 were mostly negative or failed to separate from placebo.
Esketamine in Adolescents With Major Depression at Imminent Suicide Risk
2025 · Esketamine nasal spray · Phase 2b multicenter double-blind randomized trial · 147 adolescents
Esketamine beat midazolam on depression scores at 24 hours in adolescents ages 12 to 17 at imminent suicide risk. Suicidality scores improved in all 4 treatment groups over 4 weeks without a separate suicide-scale advantage for esketamine. About 95% of participants were moderately to extremely suicidal at baseline.
Intranasal Esketamine on Suicidal Ideation and Depressive Symptoms in Treatment-Resistant Depression
2025 · Esketamine nasal spray · Prospective real-world longitudinal cohort · 80 patients
In an outpatient treatment-resistant-depression cohort, 68.4% achieved a suicidal-ideation response by the first-week clinic checkpoint on the Columbia suicide-severity scale. Male sex predicted lower odds of early suicidal-ideation response, with an odds ratio of 0.21. The weakness is open-label design with no randomization and no control arm.
Effects of Ketamine and Esketamine on Death, Suicidal Behaviour, and Suicidal Ideation in Psychiatric Disorders
2026 · Ketamine and esketamine · Systematic review and Bayesian meta-analysis · 5,671 patients across 73 trials
Intranasal esketamine’s anti-suicidal effect dropped close to zero after 24 hours, while intravenous ketamine remained small-to-medium for the first 4 weeks. Suicidal behavior events did not differ: 1.63% in active-treatment arms versus 1.72% in placebo arms, with an odds ratio of 0.98. The review says current evidence is insufficient to prove long-term reduction in suicide attempts or deaths.
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention
2026 · Esketamine nasal spray followed by CBT · Parallel-arm randomized controlled clinical trial · 93 patients
Adding 16 weeks of individual cognitive behavioral therapy after esketamine improved longer-term suicidal-ideation outcomes through week 18 on the Beck Scale for Suicide Ideation and Clinical Global Impression for Suicide Severity. The Beck Scale mean difference was -1.91, and the Clinical Global Impression difference was -0.33. The trial found no difference on the Columbia suicide-severity scale or acute suicide-related events.
Frequently Asked Questions About Ketamine for Suicidal Thoughts
1. If I might hurt myself today, should I call a ketamine clinic or go to the ER?
Go to the ER now or tap to call 911. If you have a weapon, pills, a plan, a timeline, a suicide note, or the feeling that you cannot stop yourself, outpatient ketamine is not the first step. Physical safety comes first.
A ketamine clinic can evaluate passive or non-imminent suicidal ideation. It cannot replace emergency care when you might act today. In immediate danger, use the ER, tap to call 988, tap to text 988, or tap to chat with 988.
2. How fast can IV ketamine reduce suicidal thoughts?
IV ketamine can reduce suicidal ideation within hours in controlled trials. In one emergency-department trial, 88% of acutely suicidal patients receiving IV ketamine reached remission from suicidal ideation within three hours, compared with 33% receiving placebo.
In a larger hospital trial, 63% of severely suicidal patients receiving IV ketamine reached full remission by Day 3, compared with 31.6% receiving standard care plus placebo. These are not six-week antidepressant timelines. These are hour-to-day timelines.
3. Can ketamine help passive suicidal thoughts?
Passive suicidal thoughts still need medical attention. “I wish I would not wake up,” “I want to disappear,” and “I do not want to live like this” are suicidal ideation even when there is no plan or intent.
Passive suicidal ideation is often the clearest outpatient ketamine lane because the person may be safe enough for clinic screening instead of ER admission.
Call a physician-led IV or injection ketamine clinic and say: “I have chronic passive suicidal ideation, no plan, no current intent, and treatment-resistant depression. Can your physician evaluate me for ketamine therapy?”
4. Can I get ketamine if I am actively suicidal?
It depends on the level of danger. If suicidal thoughts are active but there is no immediate plan, timeline, weapon, pills, or intent to act today, a physician-led ketamine clinic may evaluate you urgently.
If you have a plan, means, timeline, or cannot stay safe, the ER comes first.
Ask the ER physician: “Does this hospital have a monitored IV ketamine or injection ketamine protocol for acute suicidal ideation?”
Most hospitals will not. Ask anyway, and ask them to document the answer in the chart.
5. Is IV ketamine better than Spravato for suicidal thoughts?
Yes, for suicide-specific evidence. IV ketamine has stronger proof for rapid reduction or remission of suicidal ideation. Spravato nasal spray can reduce depression symptoms quickly, but its label states that its effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated.
Large Spravato trials showed rapid depression improvement, but suicide-specific scores often dropped in both the Spravato and placebo groups after hospitalization and intensive standard care. That is not the same result as IV ketamine trials showing direct separation on suicidal-ideation outcomes.
6. Is one ketamine treatment enough to stop suicidal thoughts for good?
Usually no. A single IV ketamine treatment can reduce suicidal ideation fast, but the effect can fade. The stronger plan is rapid relief followed by a stabilization block, follow-up care, medication review, therapy, lethal-means restriction, and a return-to-ER plan if suicidal intent comes back.
Repeated-treatment data support this. In one repeated-infusion study, anti-suicidal response rates reached 81.7% by Day 13 and remained 73.3% at Day 26. Fast relief matters. A follow-on plan decides whether relief turns into stability.



